China SFDA Streamlines Approval Process For AIDS, Cancer Drug Imports (China)
This article was originally published in PharmAsia News
China's State FDA says it is taking steps to remove some of the country's barriers to importation of cancer drugs, and of HIV/AIDS drugs in the wake of new infection figures. Drug registration Director Zhang Wei said the SFDA has adopted a streamlined approach to approving imports of drugs in the two categories, if they demonstrate significant clinical effects in treating disease. Under the policy, the agency cuts its 150 working days for approving most drugs to just 120 for an AIDS drug. Zhang also said U.S. company Gilead's Viread (tenofovir disoproxil fumarate) second-line anti-retroviral drug cocktail is under review. (Click here for more
You may also be interested in...
Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.